Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Salestools Logo

Salestools

The #1 AI Agent for Sales teams and Go To Market teams. Sell more, faster, with less effort.

Product

  • AI Sales Agents
  • Intent Data
  • Technology Data
  • Visitor Tracking
  • Co-Pilot
  • Social Selling

Solutions

  • Customer Service
  • E-commerce
  • SaaS
  • Enterprise
  • Small Business

Resources

  • The Report
  • Documentation
  • API Reference
  • Help Center
  • Blog
  • Case Studies
  • Webinars

Company

  • About
  • Careers
  • Press
  • Contact
  • Partners

Our locations

  • New York, HQ
  • Bucharest, AI Research Lab
  • Zug, Switzerland

Β© 2026 Salestools. All rights reserved.

Data Terms & SecurityPrivacy PolicyTerms of ServiceAcceptable Use
All systems operational
Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Back to Reports
Biotech

Enveda Biosciences

Enveda Biosciences Raises $130M Series C

Boulder, COOctober 23, 20252 min read
Total Raised
$130M Series C
Valuation
Undisclosed
Employees
80-150

Enveda Biosciences Raises $130M Series C

Biotechnology company using AI and metabolomics to discover new drugs from natural products and medicinal plants

Key Highlights

  • Funding Amount: $130M Series C
  • Valuation: Undisclosed
  • Headquarters: Boulder, CO
  • Founded: 2019
  • Employees: 80-150
  • Total Raised: $175M

About the Funding Round

Enveda Biosciences has successfully closed $130M Series C in funding, marking a significant milestone in the company's growth trajectory. This investment will enable the company to accelerate product development, expand market reach, and strengthen its position in the biotech sector.

Investor Syndicate

The round was backed by a prestigious group of investors:

  • FPV Ventures
  • Kinnevik
  • Lux Capital

This diverse group of investors brings not only capital but also strategic expertise and valuable networks that will help Enveda Biosciences achieve its ambitious goals.

Market Opportunity

The biotech market continues to experience rapid growth, driven by increasing demand for innovative solutions and digital transformation across industries. Enveda Biosciences's unique approach and proven technology position it well to capture significant market share in the coming years.

Company Background

Founded in 2019 and headquartered in Boulder, CO, Enveda Biosciences has established itself as an innovative player in the biotech space. With 80-150 employees, the company has built a strong team focused on delivering exceptional value to customers.

Next Steps

With this new funding, Enveda Biosciences plans to:

  • Accelerate product development and innovation
  • Expand into new markets and geographies
  • Grow the team across engineering, sales, and operations
  • Strengthen partnerships with key industry players
  • Scale infrastructure to support rapid growth

Industry Impact

This funding round represents a strong vote of confidence in Enveda Biosciences's vision and execution. The investment will help drive innovation in the biotech sector and create new opportunities for customers and partners.


For more information about Enveda Biosciences, visit their website or contact their press office.

Company Info

Headquarters
Boulder, CO
Founded
2019
Team Size
80-150

Investors (3)

F
FPV VenturesLead
Venture Capital
Venture capital firm
K
Kinnevik
Strategic Investor
Swedish investment firm
L
Lux Capital
Venture Capital
Venture capital firm backing science and technology ventures

Topics

Venture Capital(907)Series(543)BiotechFunding RoundCO

Share

Related Reports

Biotech
AusperBio

AusperBio Raises $73M Series B

Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials

David Chen
David Chen
Dec 30, 2025
0 min readβ€’$73M Series B
Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min readβ€’$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min readβ€’$120M Series C

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free